KeyBanc last night upgraded Thermo Fisher (TMO) to Overweight from Sector Weight with a $750 price target The firm cites improving macro conditions and the company’s “strong execution” for the upgrade. Bopharma spend is normalizing and key areas like bio-production and research and safety are seeing outsized growth, the analyst tells investors in a research note. KeyBanc is also positive on Thermo’s precise acquisition strategy, which it believes should drive accelerating growth.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMO:
- Thermo Fisher upgraded to Overweight from Sector Weight at KeyBanc
- Teva, Fastly, MP Materials, Lemonade, Thermo Fisher: Insider Sales Unveiled!
- Carvana, Zscaler, MPLX, EPD, Thermo Fisher Trending by Analysts
- Thermo Fisher expands bioprocessing capabilities across Asia
- Thermo Fisher Issues €2.1 Billion in Senior Notes